nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylpropanolamine—L-Phenylalanine—Liothyronine—hypothyroidism	0.746	1	CrCrCtD
Phenylpropanolamine—Renal tubular necrosis—Liotrix—hypothyroidism	0.0139	0.092	CcSEcCtD
Phenylpropanolamine—DRD1—nerve—hypothyroidism	0.00625	0.104	CbGeAlD
Phenylpropanolamine—Arrhythmia—Liothyronine—hypothyroidism	0.00618	0.0408	CcSEcCtD
Phenylpropanolamine—SLC6A3—nerve—hypothyroidism	0.00502	0.0832	CbGeAlD
Phenylpropanolamine—Tachycardia—Liothyronine—hypothyroidism	0.00479	0.0317	CcSEcCtD
Phenylpropanolamine—Irritability—Levothyroxine—hypothyroidism	0.00469	0.0309	CcSEcCtD
Phenylpropanolamine—Irritability—Dextrothyroxine—hypothyroidism	0.00469	0.0309	CcSEcCtD
Phenylpropanolamine—Hypotension—Liothyronine—hypothyroidism	0.00459	0.0303	CcSEcCtD
Phenylpropanolamine—CYP1A2—urine—hypothyroidism	0.00451	0.0748	CbGeAlD
Phenylpropanolamine—SLC6A2—nerve—hypothyroidism	0.00405	0.0671	CbGeAlD
Phenylpropanolamine—MAOA—nerve—hypothyroidism	0.00373	0.0619	CbGeAlD
Phenylpropanolamine—Irritability—Liotrix—hypothyroidism	0.00345	0.0228	CcSEcCtD
Phenylpropanolamine—Flushing—Levothyroxine—hypothyroidism	0.00315	0.0208	CcSEcCtD
Phenylpropanolamine—Flushing—Dextrothyroxine—hypothyroidism	0.00315	0.0208	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Levothyroxine—hypothyroidism	0.00303	0.02	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Dextrothyroxine—hypothyroidism	0.00303	0.02	CcSEcCtD
Phenylpropanolamine—Tension—Levothyroxine—hypothyroidism	0.0029	0.0192	CcSEcCtD
Phenylpropanolamine—Tension—Dextrothyroxine—hypothyroidism	0.0029	0.0192	CcSEcCtD
Phenylpropanolamine—Nervousness—Dextrothyroxine—hypothyroidism	0.00287	0.019	CcSEcCtD
Phenylpropanolamine—Nervousness—Levothyroxine—hypothyroidism	0.00287	0.019	CcSEcCtD
Phenylpropanolamine—Tremor—Dextrothyroxine—hypothyroidism	0.00277	0.0183	CcSEcCtD
Phenylpropanolamine—Tremor—Levothyroxine—hypothyroidism	0.00277	0.0183	CcSEcCtD
Phenylpropanolamine—Agitation—Dextrothyroxine—hypothyroidism	0.00272	0.0179	CcSEcCtD
Phenylpropanolamine—Agitation—Levothyroxine—hypothyroidism	0.00272	0.0179	CcSEcCtD
Phenylpropanolamine—Anxiety—Dextrothyroxine—hypothyroidism	0.00251	0.0166	CcSEcCtD
Phenylpropanolamine—Anxiety—Levothyroxine—hypothyroidism	0.00251	0.0166	CcSEcCtD
Phenylpropanolamine—Confusional state—Dextrothyroxine—hypothyroidism	0.00243	0.0161	CcSEcCtD
Phenylpropanolamine—Confusional state—Levothyroxine—hypothyroidism	0.00243	0.0161	CcSEcCtD
Phenylpropanolamine—Tachycardia—Dextrothyroxine—hypothyroidism	0.00235	0.0156	CcSEcCtD
Phenylpropanolamine—Tachycardia—Levothyroxine—hypothyroidism	0.00235	0.0156	CcSEcCtD
Phenylpropanolamine—Flushing—Liotrix—hypothyroidism	0.00232	0.0153	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Liotrix—hypothyroidism	0.00223	0.0147	CcSEcCtD
Phenylpropanolamine—Insomnia—Levothyroxine—hypothyroidism	0.00218	0.0144	CcSEcCtD
Phenylpropanolamine—Insomnia—Dextrothyroxine—hypothyroidism	0.00218	0.0144	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Levothyroxine—hypothyroidism	0.00215	0.0142	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Dextrothyroxine—hypothyroidism	0.00215	0.0142	CcSEcCtD
Phenylpropanolamine—Tension—Liotrix—hypothyroidism	0.00213	0.0141	CcSEcCtD
Phenylpropanolamine—Nervousness—Liotrix—hypothyroidism	0.00211	0.0139	CcSEcCtD
Phenylpropanolamine—Vision blurred—Liotrix—hypothyroidism	0.00205	0.0135	CcSEcCtD
Phenylpropanolamine—Tremor—Liotrix—hypothyroidism	0.00204	0.0135	CcSEcCtD
Phenylpropanolamine—Agitation—Liotrix—hypothyroidism	0.002	0.0132	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Levothyroxine—hypothyroidism	0.00199	0.0131	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Dextrothyroxine—hypothyroidism	0.00199	0.0131	CcSEcCtD
Phenylpropanolamine—Anxiety—Liotrix—hypothyroidism	0.00184	0.0122	CcSEcCtD
Phenylpropanolamine—MAOA—Neurotransmitter Release Cycle—SLC5A7—hypothyroidism	0.00181	0.0428	CbGpPWpGaD
Phenylpropanolamine—Confusional state—Liotrix—hypothyroidism	0.00179	0.0118	CcSEcCtD
Phenylpropanolamine—ADRB1—heart—hypothyroidism	0.00177	0.0293	CbGeAlD
Phenylpropanolamine—Tachycardia—Liotrix—hypothyroidism	0.00173	0.0114	CcSEcCtD
Phenylpropanolamine—ADRB1—cardiovascular system—hypothyroidism	0.00167	0.0277	CbGeAlD
Phenylpropanolamine—Hypotension—Liotrix—hypothyroidism	0.00166	0.011	CcSEcCtD
Phenylpropanolamine—Insomnia—Liotrix—hypothyroidism	0.00161	0.0106	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Liotrix—hypothyroidism	0.00158	0.0104	CcSEcCtD
Phenylpropanolamine—Vomiting—Dextrothyroxine—hypothyroidism	0.00153	0.0101	CcSEcCtD
Phenylpropanolamine—Vomiting—Levothyroxine—hypothyroidism	0.00153	0.0101	CcSEcCtD
Phenylpropanolamine—Rash—Levothyroxine—hypothyroidism	0.00152	0.01	CcSEcCtD
Phenylpropanolamine—Rash—Dextrothyroxine—hypothyroidism	0.00152	0.01	CcSEcCtD
Phenylpropanolamine—Dermatitis—Levothyroxine—hypothyroidism	0.00152	0.01	CcSEcCtD
Phenylpropanolamine—Dermatitis—Dextrothyroxine—hypothyroidism	0.00152	0.01	CcSEcCtD
Phenylpropanolamine—Constipation—Liotrix—hypothyroidism	0.00152	0.01	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Liotrix—hypothyroidism	0.00146	0.00966	CcSEcCtD
Phenylpropanolamine—MAOA—adrenal cortex—hypothyroidism	0.00143	0.0237	CbGeAlD
Phenylpropanolamine—Nausea—Dextrothyroxine—hypothyroidism	0.00143	0.00946	CcSEcCtD
Phenylpropanolamine—Nausea—Levothyroxine—hypothyroidism	0.00143	0.00946	CcSEcCtD
Phenylpropanolamine—ADRA1A—heart—hypothyroidism	0.0014	0.0232	CbGeAlD
Phenylpropanolamine—MAOA—heart—hypothyroidism	0.00139	0.023	CbGeAlD
Phenylpropanolamine—ADRA1A—cardiovascular system—hypothyroidism	0.00132	0.0219	CbGeAlD
Phenylpropanolamine—MAOA—cardiovascular system—hypothyroidism	0.00131	0.0217	CbGeAlD
Phenylpropanolamine—Hypersensitivity—Liotrix—hypothyroidism	0.00131	0.00863	CcSEcCtD
Phenylpropanolamine—SLC6A2—gonad—hypothyroidism	0.00129	0.0213	CbGeAlD
Phenylpropanolamine—Dizziness—Liotrix—hypothyroidism	0.00117	0.00775	CcSEcCtD
Phenylpropanolamine—MAOA—pituitary gland—hypothyroidism	0.00116	0.0192	CbGeAlD
Phenylpropanolamine—SLC6A3—testis—hypothyroidism	0.00115	0.0191	CbGeAlD
Phenylpropanolamine—Vomiting—Liotrix—hypothyroidism	0.00113	0.00745	CcSEcCtD
Phenylpropanolamine—SLC6A2—adrenal gland—hypothyroidism	0.00112	0.0186	CbGeAlD
Phenylpropanolamine—Rash—Liotrix—hypothyroidism	0.00112	0.00739	CcSEcCtD
Phenylpropanolamine—Dermatitis—Liotrix—hypothyroidism	0.00112	0.00738	CcSEcCtD
Phenylpropanolamine—ADRA2A—heart—hypothyroidism	0.00106	0.0176	CbGeAlD
Phenylpropanolamine—SLC6A3—cerebellum—hypothyroidism	0.00106	0.0176	CbGeAlD
Phenylpropanolamine—Nausea—Liotrix—hypothyroidism	0.00105	0.00696	CcSEcCtD
Phenylpropanolamine—ADRA1A—adrenal gland—hypothyroidism	0.00104	0.0173	CbGeAlD
Phenylpropanolamine—ADRA1A—blood—hypothyroidism	0.00104	0.0173	CbGeAlD
Phenylpropanolamine—MAOA—adrenal gland—hypothyroidism	0.00103	0.0171	CbGeAlD
Phenylpropanolamine—MAOA—blood—hypothyroidism	0.00103	0.0171	CbGeAlD
Phenylpropanolamine—MAOA—thyroid gland—hypothyroidism	0.000998	0.0165	CbGeAlD
Phenylpropanolamine—ADRB2—Arf6 trafficking events—CLTC—hypothyroidism	0.000996	0.0235	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Arf6 signaling events—TSHR—hypothyroidism	0.000972	0.023	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A7—hypothyroidism	0.000972	0.023	CbGpPWpGaD
Phenylpropanolamine—MAOA—female gonad—hypothyroidism	0.000965	0.016	CbGeAlD
Phenylpropanolamine—SLC6A2—testis—hypothyroidism	0.000929	0.0154	CbGeAlD
Phenylpropanolamine—ADRA2A—gonad—hypothyroidism	0.000911	0.0151	CbGeAlD
Phenylpropanolamine—ADRA2A—pituitary gland—hypothyroidism	0.000888	0.0147	CbGeAlD
Phenylpropanolamine—CYP1A2—blood—hypothyroidism	0.000863	0.0143	CbGeAlD
Phenylpropanolamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A7—hypothyroidism	0.000861	0.0203	CbGpPWpGaD
Phenylpropanolamine—MAOA—testis—hypothyroidism	0.000856	0.0142	CbGeAlD
Phenylpropanolamine—CYP1A2—thyroid gland—hypothyroidism	0.000833	0.0138	CbGeAlD
Phenylpropanolamine—ADRA1A—liver—hypothyroidism	0.000816	0.0135	CbGeAlD
Phenylpropanolamine—MAOA—liver—hypothyroidism	0.000809	0.0134	CbGeAlD
Phenylpropanolamine—ADRA1A—cerebellum—hypothyroidism	0.000797	0.0132	CbGeAlD
Phenylpropanolamine—ADRA2A—adrenal gland—hypothyroidism	0.000794	0.0132	CbGeAlD
Phenylpropanolamine—ADRA2A—blood—hypothyroidism	0.000794	0.0131	CbGeAlD
Phenylpropanolamine—MAOA—cerebellum—hypothyroidism	0.00079	0.0131	CbGeAlD
Phenylpropanolamine—MAOA—SIDS Susceptibility Pathways—DLX2—hypothyroidism	0.000777	0.0184	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Arf6 trafficking events—TSHR—hypothyroidism	0.000768	0.0181	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—thyroid gland—hypothyroidism	0.000766	0.0127	CbGeAlD
Phenylpropanolamine—ADRA2A—female gonad—hypothyroidism	0.00074	0.0123	CbGeAlD
Phenylpropanolamine—SLC6A2—NRF2 pathway—SLC5A7—hypothyroidism	0.000701	0.0166	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—liver—hypothyroidism	0.000675	0.0112	CbGeAlD
Phenylpropanolamine—ADRA2A—testis—hypothyroidism	0.000656	0.0109	CbGeAlD
Phenylpropanolamine—SLC6A3—NRF2 pathway—SLC5A7—hypothyroidism	0.000621	0.0147	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—cerebellum—hypothyroidism	0.000606	0.01	CbGeAlD
Phenylpropanolamine—MAOA—Transmission across Chemical Synapses—SLC5A7—hypothyroidism	0.000519	0.0123	CbGpPWpGaD
Phenylpropanolamine—MAOA—SIDS Susceptibility Pathways—THRB—hypothyroidism	0.000501	0.0118	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Transmission across Chemical Synapses—SLC5A7—hypothyroidism	0.000483	0.0114	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—SLC-mediated transmembrane transport—SLC5A7—hypothyroidism	0.000442	0.0104	CbGpPWpGaD
Phenylpropanolamine—DRD1—Circadian rythm related genes—NKX2-1—hypothyroidism	0.000424	0.01	CbGpPWpGaD
Phenylpropanolamine—DRD1—G alpha (s) signalling events—TSHB—hypothyroidism	0.000402	0.00949	CbGpPWpGaD
Phenylpropanolamine—DRD1—G alpha (s) signalling events—TSHR—hypothyroidism	0.000402	0.00949	CbGpPWpGaD
Phenylpropanolamine—MAOA—Neuronal System—SLC5A7—hypothyroidism	0.000398	0.0094	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—SLC-mediated transmembrane transport—SLC5A7—hypothyroidism	0.000391	0.00924	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Neuronal System—SLC5A7—hypothyroidism	0.00037	0.00874	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.000366	0.00865	CbGpPWpGaD
Phenylpropanolamine—ADRB1—G alpha (s) signalling events—TSHB—hypothyroidism	0.000361	0.00853	CbGpPWpGaD
Phenylpropanolamine—ADRB1—G alpha (s) signalling events—TSHR—hypothyroidism	0.000361	0.00853	CbGpPWpGaD
Phenylpropanolamine—ADRB2—G alpha (s) signalling events—TSHB—hypothyroidism	0.000353	0.00835	CbGpPWpGaD
Phenylpropanolamine—ADRB2—G alpha (s) signalling events—TSHR—hypothyroidism	0.000353	0.00835	CbGpPWpGaD
Phenylpropanolamine—MAOA—Transmission across Chemical Synapses—NEFL—hypothyroidism	0.000335	0.00791	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.000324	0.00766	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Transmission across Chemical Synapses—NEFL—hypothyroidism	0.000311	0.00735	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—NRF2 pathway—SLC5A5—hypothyroidism	0.00028	0.00662	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—G alpha (12/13) signalling events—VAV3—hypothyroidism	0.000267	0.00632	CbGpPWpGaD
Phenylpropanolamine—MAOA—Neuronal System—NEFL—hypothyroidism	0.000256	0.00606	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—NRF2 pathway—SLC5A5—hypothyroidism	0.000248	0.00586	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Neuronal System—NEFL—hypothyroidism	0.000238	0.00563	CbGpPWpGaD
Phenylpropanolamine—DRD1—G alpha (s) signalling events—AVP—hypothyroidism	0.000237	0.00559	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—G alpha (q) signalling events—TRH—hypothyroidism	0.000236	0.00558	CbGpPWpGaD
Phenylpropanolamine—MAOA—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000231	0.00545	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000224	0.0053	CbGpPWpGaD
Phenylpropanolamine—DRD1—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.000215	0.00508	CbGpPWpGaD
Phenylpropanolamine—ADRB1—G alpha (s) signalling events—AVP—hypothyroidism	0.000213	0.00503	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—TRH—hypothyroidism	0.000211	0.00499	CbGpPWpGaD
Phenylpropanolamine—ADRB2—G alpha (s) signalling events—AVP—hypothyroidism	0.000208	0.00492	CbGpPWpGaD
Phenylpropanolamine—MAOA—SIDS Susceptibility Pathways—AVP—hypothyroidism	0.000199	0.00471	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000199	0.0047	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.000193	0.00456	CbGpPWpGaD
Phenylpropanolamine—DRD1—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000192	0.00453	CbGpPWpGaD
Phenylpropanolamine—DRD1—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000192	0.00453	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.000189	0.00447	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000186	0.00439	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.000176	0.00417	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000172	0.00407	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000172	0.00407	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000168	0.00398	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000168	0.00398	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000165	0.00389	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR ligand binding—TRH—hypothyroidism	0.000164	0.00387	CbGpPWpGaD
Phenylpropanolamine—DRD1—Circadian rythm related genes—AVP—hypothyroidism	0.000161	0.0038	CbGpPWpGaD
Phenylpropanolamine—DRD1—G alpha (s) signalling events—POMC—hypothyroidism	0.000157	0.00372	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.000156	0.00369	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.000156	0.00369	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—TRH—hypothyroidism	0.000147	0.00348	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR ligand binding—TSHB—hypothyroidism	0.000146	0.00345	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR ligand binding—TSHR—hypothyroidism	0.000146	0.00345	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.000145	0.00343	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—IYD—hypothyroidism	0.000145	0.00341	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—TRH—hypothyroidism	0.000144	0.0034	CbGpPWpGaD
Phenylpropanolamine—ADRB1—G alpha (s) signalling events—POMC—hypothyroidism	0.000141	0.00334	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000139	0.00329	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000139	0.00329	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.000139	0.00328	CbGpPWpGaD
Phenylpropanolamine—ADRB2—G alpha (s) signalling events—POMC—hypothyroidism	0.000138	0.00327	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—TSHB—hypothyroidism	0.000131	0.0031	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—TSHR—hypothyroidism	0.000131	0.0031	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000129	0.00306	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000129	0.00306	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—TSHR—hypothyroidism	0.000128	0.00303	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—TSHB—hypothyroidism	0.000128	0.00303	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—G alpha (q) signalling events—AVP—hypothyroidism	0.000124	0.00293	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.000123	0.00291	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—ATP5O—hypothyroidism	0.000123	0.0029	CbGpPWpGaD
Phenylpropanolamine—MAOA—Biological oxidations—POMC—hypothyroidism	0.000122	0.00289	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—TRH—hypothyroidism	0.000119	0.00281	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—TPO—hypothyroidism	0.000116	0.00273	CbGpPWpGaD
Phenylpropanolamine—DRD1—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.000113	0.00267	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—hypothyroidism	0.000111	0.00262	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—TRH—hypothyroidism	0.000111	0.00261	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—TSHB—hypothyroidism	0.000106	0.00251	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—TSHR—hypothyroidism	0.000106	0.00251	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000105	0.00248	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Platelet activation, signaling and aggregation—VAV3—hypothyroidism	0.000105	0.00247	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.000101	0.0024	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	9.93e-05	0.00235	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—TSHB—hypothyroidism	9.86e-05	0.00233	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—TSHR—hypothyroidism	9.86e-05	0.00233	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—IYD—hypothyroidism	9.66e-05	0.00228	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—TRH—hypothyroidism	9.25e-05	0.00218	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	8.97e-05	0.00212	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR ligand binding—AVP—hypothyroidism	8.59e-05	0.00203	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	8.5e-05	0.00201	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—TRH—hypothyroidism	8.4e-05	0.00198	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—TRH—hypothyroidism	8.31e-05	0.00196	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—TSHB—hypothyroidism	8.24e-05	0.00195	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—TSHR—hypothyroidism	8.24e-05	0.00195	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	8.21e-05	0.00194	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—ATP5O—hypothyroidism	8.21e-05	0.00194	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—TRH—hypothyroidism	8.13e-05	0.00192	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	7.95e-05	0.00188	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—SH2B3—hypothyroidism	7.86e-05	0.00186	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—AVP—hypothyroidism	7.73e-05	0.00183	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—TPO—hypothyroidism	7.72e-05	0.00182	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	7.63e-05	0.0018	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—AVP—hypothyroidism	7.56e-05	0.00179	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—TRH—hypothyroidism	7.55e-05	0.00178	CbGpPWpGaD
Phenylpropanolamine—DRD1—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	7.5e-05	0.00177	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—TSHB—hypothyroidism	7.48e-05	0.00177	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—TSHR—hypothyroidism	7.48e-05	0.00177	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—TSHB—hypothyroidism	7.41e-05	0.00175	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—TSHR—hypothyroidism	7.41e-05	0.00175	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—TRH—hypothyroidism	7.38e-05	0.00174	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—TSHB—hypothyroidism	7.25e-05	0.00171	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—TSHR—hypothyroidism	7.25e-05	0.00171	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—Transmembrane transport of small molecules—AVP—hypothyroidism	7.06e-05	0.00167	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	6.74e-05	0.00159	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—TSHR—hypothyroidism	6.73e-05	0.00159	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—TSHB—hypothyroidism	6.73e-05	0.00159	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—TRH—hypothyroidism	6.73e-05	0.00159	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	6.6e-05	0.00156	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—TSHB—hypothyroidism	6.58e-05	0.00156	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—TSHR—hypothyroidism	6.58e-05	0.00156	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Platelet activation, signaling and aggregation—IGF1—hypothyroidism	6.44e-05	0.00152	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—G alpha (i) signalling events—POMC—hypothyroidism	6.38e-05	0.00151	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Transmembrane transport of small molecules—AVP—hypothyroidism	6.26e-05	0.00148	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—AVP—hypothyroidism	6.25e-05	0.00148	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—TRH—hypothyroidism	6.25e-05	0.00148	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—TRH—hypothyroidism	6.11e-05	0.00144	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—TSHB—hypothyroidism	5.99e-05	0.00142	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—TSHR—hypothyroidism	5.99e-05	0.00142	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—AVP—hypothyroidism	5.81e-05	0.00137	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CLTC—hypothyroidism	5.74e-05	0.00136	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR ligand binding—POMC—hypothyroidism	5.71e-05	0.00135	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—TRH—hypothyroidism	5.68e-05	0.00134	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—TSHB—hypothyroidism	5.57e-05	0.00132	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—TSHR—hypothyroidism	5.57e-05	0.00132	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	5.46e-05	0.00129	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—TSHR—hypothyroidism	5.44e-05	0.00129	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—TSHB—hypothyroidism	5.44e-05	0.00129	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—VAV3—hypothyroidism	5.39e-05	0.00127	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—TSHB—hypothyroidism	5.35e-05	0.00126	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—IYD—hypothyroidism	5.33e-05	0.00126	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CLTC—hypothyroidism	5.16e-05	0.00122	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—POMC—hypothyroidism	5.13e-05	0.00121	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	5.07e-05	0.0012	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—TSHB—hypothyroidism	5.06e-05	0.0012	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—TSHR—hypothyroidism	5.06e-05	0.0012	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CLTC—hypothyroidism	5.05e-05	0.00119	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—VAV3—hypothyroidism	5.04e-05	0.00119	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—POMC—hypothyroidism	5.02e-05	0.00119	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TRH—hypothyroidism	4.96e-05	0.00117	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—AVP—hypothyroidism	4.86e-05	0.00115	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PIK3C2A—hypothyroidism	4.77e-05	0.00113	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—VAV3—hypothyroidism	4.58e-05	0.00108	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—VAV3—hypothyroidism	4.53e-05	0.00107	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ATP5O—hypothyroidism	4.53e-05	0.00107	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Biological oxidations—POMC—hypothyroidism	4.52e-05	0.00107	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TRH—hypothyroidism	4.46e-05	0.00105	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—VAV3—hypothyroidism	4.43e-05	0.00105	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TSHR—hypothyroidism	4.42e-05	0.00104	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TSHB—hypothyroidism	4.42e-05	0.00104	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—AVP—hypothyroidism	4.41e-05	0.00104	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—AVP—hypothyroidism	4.37e-05	0.00103	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TRH—hypothyroidism	4.36e-05	0.00103	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—AVP—hypothyroidism	4.27e-05	0.00101	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—TPO—hypothyroidism	4.26e-05	0.00101	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CLTC—hypothyroidism	4.17e-05	0.000986	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—POMC—hypothyroidism	4.15e-05	0.000982	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—VAV3—hypothyroidism	4.12e-05	0.000973	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—VAV3—hypothyroidism	4.03e-05	0.000951	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—SLC5A5—hypothyroidism	4e-05	0.000946	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TSHB—hypothyroidism	3.97e-05	0.000939	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TSHR—hypothyroidism	3.97e-05	0.000939	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—AVP—hypothyroidism	3.97e-05	0.000937	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	3.95e-05	0.000933	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—SH2B3—hypothyroidism	3.94e-05	0.000931	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TSHB—hypothyroidism	3.89e-05	0.000919	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TSHR—hypothyroidism	3.89e-05	0.000919	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—AVP—hypothyroidism	3.88e-05	0.000917	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CLTC—hypothyroidism	3.88e-05	0.000917	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—POMC—hypothyroidism	3.86e-05	0.000912	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—VAV3—hypothyroidism	3.67e-05	0.000867	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TRH—hypothyroidism	3.61e-05	0.000853	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—TSHB—hypothyroidism	3.57e-05	0.000844	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—SH2B3—hypothyroidism	3.54e-05	0.000837	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—AVP—hypothyroidism	3.53e-05	0.000835	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—SH2B3—hypothyroidism	3.47e-05	0.000819	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—VAV3—hypothyroidism	3.41e-05	0.000805	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TRH—hypothyroidism	3.35e-05	0.000792	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—VAV3—hypothyroidism	3.33e-05	0.000787	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—IGF1—hypothyroidism	3.32e-05	0.000785	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—AVP—hypothyroidism	3.28e-05	0.000776	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—POMC—hypothyroidism	3.23e-05	0.000763	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TSHB—hypothyroidism	3.22e-05	0.00076	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TSHR—hypothyroidism	3.22e-05	0.00076	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—AVP—hypothyroidism	3.21e-05	0.000758	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3C2A—hypothyroidism	3.19e-05	0.000753	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—VAV3—hypothyroidism	3.09e-05	0.000731	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TSHB—hypothyroidism	2.99e-05	0.000706	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TSHR—hypothyroidism	2.99e-05	0.000706	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—AVP—hypothyroidism	2.98e-05	0.000704	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—POMC—hypothyroidism	2.93e-05	0.000693	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PRL—hypothyroidism	2.92e-05	0.000691	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—POMC—hypothyroidism	2.9e-05	0.000686	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SH2B3—hypothyroidism	2.87e-05	0.000677	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—POMC—hypothyroidism	2.84e-05	0.000671	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—VAV3—hypothyroidism	2.7e-05	0.000639	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—SLC5A5—hypothyroidism	2.68e-05	0.000632	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SH2B3—hypothyroidism	2.66e-05	0.000629	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—POMC—hypothyroidism	2.64e-05	0.000623	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PRL—hypothyroidism	2.63e-05	0.000621	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—AVP—hypothyroidism	2.61e-05	0.000616	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—POMC—hypothyroidism	2.58e-05	0.000609	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PRL—hypothyroidism	2.57e-05	0.000608	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—VAV3—hypothyroidism	2.43e-05	0.000575	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—VAV3—hypothyroidism	2.38e-05	0.000562	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—POMC—hypothyroidism	2.35e-05	0.000555	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—AVP—hypothyroidism	2.34e-05	0.000554	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—AVP—hypothyroidism	2.29e-05	0.000541	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—POMC—hypothyroidism	2.18e-05	0.000516	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—POMC—hypothyroidism	2.13e-05	0.000504	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PRL—hypothyroidism	2.13e-05	0.000503	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—POMC—hypothyroidism	2.09e-05	0.000495	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—POMC—hypothyroidism	1.98e-05	0.000468	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PRL—hypothyroidism	1.98e-05	0.000467	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—TSHB—hypothyroidism	1.97e-05	0.000466	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—VAV3—hypothyroidism	1.97e-05	0.000465	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—AVP—hypothyroidism	1.9e-05	0.000448	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—VAV3—hypothyroidism	1.83e-05	0.000432	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—AVP—hypothyroidism	1.76e-05	0.000416	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3C2A—hypothyroidism	1.76e-05	0.000415	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	1.73e-05	0.00041	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—POMC—hypothyroidism	1.73e-05	0.000409	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IGF1—hypothyroidism	1.67e-05	0.000394	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—POMC—hypothyroidism	1.56e-05	0.000368	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—POMC—hypothyroidism	1.52e-05	0.00036	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IGF1—hypothyroidism	1.5e-05	0.000354	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—SLC5A5—hypothyroidism	1.48e-05	0.000349	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IGF1—hypothyroidism	1.46e-05	0.000346	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—POMC—hypothyroidism	1.4e-05	0.000331	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—POMC—hypothyroidism	1.26e-05	0.000298	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IGF1—hypothyroidism	1.21e-05	0.000286	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—POMC—hypothyroidism	1.17e-05	0.000277	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IGF1—hypothyroidism	1.13e-05	0.000266	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—POMC—hypothyroidism	7.73e-06	0.000183	CbGpPWpGaD
